Second-generation antipsychotics and metabolic syndrome: a role for mitochondria
(2023)
Journal Article
Psychosis is a known risk factor for developing metabolic syndrome (MetS). The risk is even greater in patients who are taking second-generation antipsychotics (SGAs). SGAs exacerbate metabolic abnormalities and lead to a 3-fold increased risk of sev... Read More about Second-generation antipsychotics and metabolic syndrome: a role for mitochondria.